Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD

NCT03744806 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2018-11-16

No results posted yet for this study

Summary

The aim of this study is to evaluate the effect of repeated intravitreal bevacizumab injections on blood-aqueous barrier permeability in eyes with neovascular age-related macular degeneration (AMD).

Conditions

  • Exudative Age-related Macular Degeneration

Interventions

DRUG

Bevacizumab Injection

Sponsors & Collaborators

  • Medical University of Lublin

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-09-30
Completion
2018-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03744806 on ClinicalTrials.gov